Brian D. Koh
Impact in
- Cancer Research top 5%
- Sesquiterpenes and Asteraceae Studies
- NF-κB Signaling Pathways
-
- Natural product bioactivities and synthesis
- DNA Repair Mechanisms
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 2
- DNA Repair Mechanisms 1
- Ubiquitin and proteasome pathways 1
- Gene expression and cancer classification 1
- Protein Degradation and Inhibitors 1
- Co-authors
- Craig M. Crews (5 shared papers)Benjamin H. Kwok (2 shared papers)Mikael Elofsson (2 shared papers)MacKevin Ndubuisi (1 shared paper)Scott H. Kaufmann (7 shared papers)Karen S. Flatten (5 shared papers)Judith E. Karp (6 shared papers)Kevin L. Peterson (4 shared papers)
- Journals
- Clinical Cancer Research (3 papers)Blood (3 papers)Investigational New Drugs (1 paper)Journal of Biological Chemistry (1 paper)Leukemia (1 paper)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Brian D. Koh
17 papers receiving 939 citations
Peers
Comparison fields: 5 of 81
- Cancer Research 276
- Molecular Biology 624
- Toxicology 27
- Oncology 198
- Hematology 64
Countries citing papers authored by Brian D. Koh
This map shows the geographic impact of Brian D. Koh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian D. Koh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian D. Koh more than expected).
Fields of papers citing papers by Brian D. Koh
This network shows the impact of papers produced by Brian D. Koh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian D. Koh. The network helps show where Brian D. Koh may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian D. Koh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2001 | 438 | |
| 2 | Linking gene expression patterns to therapeutic groups in breast cancer. | 2000 | 101 |
| 3 | 2011 | 83 | |
| 4 | 2013 | 63 | |
| 5 | 2014 | 51 | |
| 6 | 2012 | 43 | |
| 7 | 2018 | 32 | |
| 8 | 2016 | 28 | |
| 9 | 2002 | 24 | |
| 10 | 2016 | 23 | |
| 11 | 2022 | 18 | |
| 12 | 2002 | 14 | |
| 13 | 2002 | 11 | |
| 14 | 2002 | 9 | |
| 15 | 2015 | 8 | |
| 16 | 2011 | 4 | |
| 17 | 2016 | 2 |
About Brian D. Koh
Brian D. Koh is a scholar working on Molecular Biology, Pharmacology, Oncology, Cancer Research and Genetics, having authored 17 papers that have together received 952 indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (2 papers), Acute Myeloid Leukemia Research (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), DNA Repair Mechanisms (1 paper), Ubiquitin and proteasome pathways (1 paper), Gene expression and cancer classification (1 paper), Sesquiterpenes and Asteraceae Studies (1 paper) and Protein Degradation and Inhibitors (1 paper). The work is most often cited by research in Cancer Research (276 citations), Molecular Biology (624 citations), Toxicology (27 citations), Oncology (198 citations) and Hematology (64 citations). Brian D. Koh has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Craig M. Crews, Benjamin H. Kwok, Mikael Elofsson, MacKevin Ndubuisi, Scott H. Kaufmann, Karen S. Flatten, Judith E. Karp, Kevin L. Peterson, Allan D. Hess and B. Douglas Smith. Their work appears in journals such as Clinical Cancer Research, Blood, Investigational New Drugs, Journal of Biological Chemistry and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.